retatrutide patent eli lilly stock jumps on Phase 3 weight loss results Eli Lilly infiltrates anti-obesity market

Produktinformation i korthet 6 mg Retatrutide Frfylld premixed forskningspenna Totalt 120 enheter 50 g per enhet Ingen rekonstituering krvs Triple agonist fr GLP-1R, GIPR och glukagonreceptorn Avsedd fr laboratorieforskning Peptidprofil Retatrutide och dess tre receptorsystem Retatrutide r utvecklad fr samtidig aktivitet vid GLP-1-, GIP- och glukagonreceptorerna

Liraglutide-induced injection site reaction

Results continued to improve over the full treatment period of 48 weeks

Covariates Clinically relevant covariates, known to influence survival and cardiovascular or kidney outcomes, were carefully selected to ensure balanced comparisons between study groups